At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Imiquimod +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of TLR7 Agonist Imiquimod, Cyclophosphamide, and Radiotherapy in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
In Brief
A Phase 2 clinical trial evaluating Radiation, Imiquimod, and 1 other intervention for Breast Cancer and 2 related conditions. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases from breast cancer in the second part (Phase II). Currently this trial is in its Phase II part.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionJul 2016
Study CompletionAug 2016
TodayJul 2026
First PostedAug 22, 2011
Enrollment StartAug 19, 2011
Primary CompletionJul 1, 2016
Study CompletionAug 6, 2016
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 14.9 years ago
Interventions
Radiationradiation
Imiquimoddrug
Cyclophosphamidedrug